Zhifei also gets the right of first refusal to be the exclusive partner for Arexvy, which is not yet approved in China, but has been cleared in the US, Europe, and Japan to prevent RSV lower ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

GSK has reported new clinical data pointing to a benefit with its respiratory syncytial virus (RSV) vaccine Arexvy when used to treat a younger age group than the over-60s for whom it is approved ...

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

GSK is taking to the airwaves to talk RSV, presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games.

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.

The FDA approved both RSVPreF3 (Arexvy; GSK) and RSVpreF (Abrysvo; Pfizer) in May 2023. 2,3 A year later, the FDA approved the mRNA-1345 (mRESVIA; Moderna) vaccine for RSV for adults 60 years and ...

In July, the FDA agreed to review the application to extend the indication of Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 18-49 who are at increased risk.

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.

For older adults, two RSV vaccines (Arexvy and Abrysvo) are available, with a single dose recommended for everyone aged 75+, those over 60 at higher risk due to medical conditions, and all ...